A Phase 3, Multi-center, Randomized, Double-Masked and Vehicle-Controlled Study Evaluating the Efficacy and Safety of the Melanocortin, PL9643 Ophthalmic Solution, Compared to Vehicle in Subjects with Dry Eye
Latest Information Update: 15 May 2025
At a glance
- Drugs PL 9643 (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms MELODY-1
- Sponsors Palatin Technologies
Most Recent Events
- 08 May 2025 According to a Palatin Technologies media release, company presented data from this study in a poster presentation at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
- 29 Apr 2025 Results presented in the Palatin Technologies Media Release.
- 24 Oct 2024 Results presented in the Palatin Technologies Media Release